Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

Leslie Calapre; Lydia Warburton; Michael Millward; Mel Ziman; Elin S. Gray

doi:10.1016/j.canlet.2017.06.030

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

Leslie Calapre, Lydia Warburton, Michael Millward, Mel Ziman, Elin S. Gray

Research output: Contribution to journal › Short survey › peer-review

93 Citations (Scopus)

Abstract

Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.

Original language	English
Pages (from-to)	62-69
Number of pages	8
Journal	Cancer Letters
Volume	404
DOIs	https://doi.org/10.1016/j.canlet.2017.06.030
Publication status	Published - 28 Sept 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2017.06.030

Cite this

@article{9f7ba7a4ef584471adf5b531b6e905ed,

title = "Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma",

abstract = "Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.",

keywords = "Cell-free DNA, Circulating tumour DNA, ctDNA, Liquid biopsy, Melanoma",

author = "Leslie Calapre and Lydia Warburton and Michael Millward and Mel Ziman and Gray, {Elin S.}",

year = "2017",

month = sep,

day = "28",

doi = "10.1016/j.canlet.2017.06.030",

language = "English",

volume = "404",

pages = "62--69",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier",

}

TY - JOUR

T1 - Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

AU - Calapre, Leslie

AU - Warburton, Lydia

AU - Millward, Michael

AU - Ziman, Mel

AU - Gray, Elin S.

PY - 2017/9/28

Y1 - 2017/9/28

N2 - Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.

AB - Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.

KW - Cell-free DNA

KW - Circulating tumour DNA

KW - ctDNA

KW - Liquid biopsy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85025468650&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.06.030

DO - 10.1016/j.canlet.2017.06.030

M3 - Short survey

C2 - 28687355

AN - SCOPUS:85025468650

SN - 0304-3835

VL - 404

SP - 62

EP - 69

JO - Cancer Letters

JF - Cancer Letters

ER -

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this